TheraP: A randomised phase 2 trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel - initial results (ANZUP protocol 1603).

作者： Margaret McJannett , Michael Hofman , Scott Williams , Ian D Davis , Martin Stockler

DOI:

关键词: